The indications for fsrt were postoperative residual disease in 5 patients (38.4%) at a median of 3.2 months from surgery (range: 1.2–7.4 months), recurrent disease in 7 patients (53.8%) at a median of 12.4 months from surgery (range: 5.2–53.3 months), and primary therapy in 1 patient. Table I summarizes patient characteristics. All patients underwent complete clinical evaluation before fsrt, including consultations in ophthalmology and endocrinology.

A pretreatment 2-mm global T1 contrast-enhanced magnetic resonance imaging (mri) study was obtained for all patients and co-registered to a 3-mm treatment planning computed tomography scan. Tumour and normal structures were contoured, and a 3-mm margin was then added to the gross tumour volume to generate the planning target volume (ptv). Treatment plans were typically designed using 4–6 static 6-MV non-coplanar micro–multileaf collimation portals (Brainscan 5.21: BrainLAB AG, Heimstetten Germany). Typically, a dose of 50.4 Gy was prescribed to a median isodose surface of 90.1% (range: 76.9%–95.2%) in 1.8-Gy fractions over 5.5 weeks. A different regimen was used to treat 2 patients: one patient was treated to 45 Gy; the other, whose tumour had malignant features, received 60 Gy. Patients were immobilized using a noninvasive thermoplastic mask system (BrainLAB AG), with the patient supine in neutral head position.

The use of the stereotactic technique provided appropriate conformation of the prescribed dose to the ptv with a median planning isodose–tumour volume conformity index of 1.4 (range: 1.2–1.8). Between 93.3% and 99.1% (median: 97%) of the ptv was covered by the prescription isodose. In all patients, a portion of the optic chiasm and the optic nerves was spared from receiving the prescribed radiation dose. Because of proximity to the target, a small portion of the optic apparatus could have received a dose equal to or slightly higher than the prescribed dose. Hot spots of up to 110% of the prescribed dose were on occasion delivered to 5%–16% of the volume of the optic chiasm or the optic nerves. Figure 1 shows an averaged dose–volume histogram for all patients, and Table II summarizes the treatment parameters.

Treatments were well tolerated. No acute effects at grade 2 or higher were recorded, and to date, no late toxicity has been observed. All patients completed the prescribed radiation dose without treatment interruption.

At a median follow-up of 27 months (range: 10–82 months), the local control rate—defined as freedom from radiologic disease progression—was 100%. In 2 patients (15.4%), an objective radiologic response was achieved. Complete tumour resolution was achieved in 1 patient with a large residual adrenocorticotropic hormone (acth)–secreting macroadenoma. His follow-up mri study revealed no radiologic evidence of disease 4 years after fsrt (Figure 2). Another patient who received primary fsrt for a growth hormone–secreting adenoma achieved a partial (50% or better) reduction in the original tumour volume. Radiologic findings were stable in the other 11 patients.

Of the 4 patients with functional macroadenomas, only 1 patient with an acth-secreting macroadenoma showed hormone level normalization from the pretreatment elevated level. This response was associated with a complete radiologic response (Figure 2). No significant change in hormone level was observed in the other 3 patients.

Pre-existing panhypopituitarism in 3 patients (23%) required continued hormone replacement therapy during and after fsrt. At last endocrinology follow-up, no manifestations of pituitary insufficiency were observed in the other 6 patients who presented with normal pituitary function.

Despite well-established long-term tumour control rates for adjuvant radiation therapy in pituitary macroadenoma, use of radiation is limited or frequently delayed because of concerns over potential late complications involving the optic apparatus, the pituitary gland, or the brain parenchyma ^13,14. The most common complication after postoperative radiation therapy is pituitary hormone deficiency, whose reported rate ranges between 30% and 50% ¹⁵. The risk of developing hormone insufficiency is persistent for up to more than 15 years after radiotherapy. Brada et al. reported a need for hormonal replacement therapy in 30% and 50% of patients 10 and 19 years after radiotherapy ¹⁶. Optic neuropathy is a serious complication, but it is rare after fractionated radiotherapy to doses of 45–54 Gy; Parsons et al. reported no optic nerve injuries in 106 optic nerves that received a total radiation dose of less than 59 Gy ¹⁷. The reported risk of optic neuropathy after fractionated radiotherapy for pituitary adenomas lies between 1% and 5% ³. Radiation-induced secondary intracranial tumours in the form of sarcomas, meningiomas, and gliomas were also reported with cumulative risks of 1.3% and 1.9% after 10 and 20 years respectively ¹⁸. Other reported complications include brain necrosis, cerebrovascular disease, and neurocognitive dysfunction, although these risks are not well defined nor is the contribution of radiation to these events ^3,17,18.

The foregoing risk estimates are derived from series in which less-conformal techniques were used to deliver radiation therapy. The image-guided stereotactic techniques currently available allow for more precise targeting, more-conformal dose distributions, and steeper dose falloff beyond the target volume, thereby reducing normal-tissue exposure and, consequently, expected late toxicities. Figure 3 depicts the dosimetric difference between conventional 3-field and fsrt plans. Not only does the latter plan provide better target coverage (the ptv is entirely within the prescription isodose), but also significant sparing of the optic chiasm.

Stereotactic radiosurgery (srs), either Gamma Knife (Elekta, Stockholm, Sweden) or linear accelerator–based, has frequently been used in the treatment of pituitary adenoma, with crude local control rates ranging from 90% to 100% and widely variable hormonal cure rates ranging from 0% to 100% ^3,4. In a recent retrospective comparison, no statistically significant differences were observed between srs and conventionally fractionated conformal radiotherapy in terms of objective response rate (81.8% at 4 years) and local control rate (97% at 4 years). However, a trend toward a higher complete hormonal response rate was observed in the srs group (43.8% vs. 36.4%), with a shorter median time to complete hormonal remission (26 months in the srs group and 63 months in the fractionated radiotherapy group). No patients developed new visual deterioration, and of 11 patients who required post-treatment hormone replacement therapy, only 1 was in the srs group ¹⁹.

Reports from retrospective trials of srs specifically addressing pituitary macroadenoma show similar results ^20,21, although in one series, macroadenomas tended to have worse local control. Local failures were also more common in cases in which the tumour extended into the cavernous sinus ²⁰.

The limitation of srs is radiation-induced optic neuropathy after a single large radiation dose. The risk is low with doses below 10 Gy, but it increases to 26.7% at doses of between 10 Gy and 15 Gy. Doses higher than 15 Gy are associated with a markedly increased risk that may reach 77.8% ²¹. The current consensus is to limit radiosurgery to smaller adenomas removed from the optic apparatus (usually 3–5 mm) and to keep the dose to the optic apparatus below 8–10 Gy ³. Whether the outcomes for small tumours are different for srs and for fractionated radiotherapy remains controversial. Treatment selection is often guided by institutional preference and treatment device rather than by clinical evidence.

Currently, the use of fsrt is growing. The technique combines the precise treatment delivery of srs with the radiobiologic advantage of dose fractionation, making it the preferred technique for the treatment of large tumours or tumours closely situated to the optic apparatus. In one of the earliest retrospective reports on fsrt, Mitsumori et al. ²² reported the results of 30 patients treated with fsrt to a total dose of 45 Gy in 25 fractions, compared with 18 patients treated with srs to a dose ranging from 10 Gy to 18 Gy. The 3-year tumour control rate was not significantly different (100% for srs and 85.3% for fsrt) The median tumour volume in the srs group was much smaller, at 1.9 cm³ as compared with 5.7 cm³ in the fsrt group. The time to hormone normalization was shorter among srs patients, at 8.5 months as compared with 18 months for fsrt patients. The authors reported no radiation-induced visual complications in either group. The rates of hormone deficiency after radiotherapy were not significantly different (23% after srs vs. 20% after fsrt). The only significant difference noted was in the rate of radiation-induced brain necrosis, which was 27.8% in the srs group as compared with 0% in the fsrt group (p = 0.02). The authors recommended the use of fsrt for pituitary adenoma whenever possible.

Table III summarizes the published data on fsrt for the treatment of pituitary adenoma. Although the proportions of macroadenoma in these series were not specified, most series had to have included patients with larger tumours, given the median tumour volume range of 4.1–30.2 cm³.

Most studies have short follow-up periods. The reported local control rate ranged from 85% to 100%. The reported hormonal control rates are difficult to interpret because the definition of hormonal control varied with the study and because the number of patients with secretory adenomas was small. The same uncertainty applies to the reported visual complications, which ranged from 0% to 7%. The dose to the optic chiasm and the optic nerves, the types of visual complications, and the methods used to diagnose those complications were poorly reported in most studies.